PURPOSE: Increasing numbers of atypical femoral fractures have been reported among long-term bisphosphonate users. We evaluated clinical characteristics of atypical femoral fractures throughout Korean multicenter studies. METHODS: We retrospectively analysed the bone mineral density, prodromal symptoms before femoral fracture, and medication history of osteoporosis in 76 cases of atypical femoral fracture. RESULTS: The mean age of cases was 71.4 ± 8.8 (range, 43-89) years old. The mean follow-up period after the fracture operation was 24.5 ± 12.9 (range, 12-79) months. BMI was 23.2 ± 3.0 on average. The mean BMD of femur was -1.9 ± 1.4 (range, -4.8 to 1.3). Prodromal symptoms including thigh pain before femoral fracture appeared in 22 (28.9 %) of 76 patients. All patients included in the study used bisphosphonate. The duration of taking bisphosphonate before fracture was 36.8 ± 50.8 (one-204 months) months. Fifty-seven (75 %) of 76 patients were taking the medication for more than three years. Delayed union occurred in 43 (56.5 %) of 76 patients. Delayed union was defined as a fractured bone that did not completely heal within six months of injury. The group of having taken anti-osteoporotic medication for more than three years showed relatively longer union period compared to that for a shorter period medication group (4.8 ± 2.5 months vs 9.3 ± 3.7 months, p = 0.017). The delayed union developed in 43 (56.5 %) of 76 patients and showed a significantly higher incidence in the group with long-term therapy (five/43 vs 38/43, p = 0.021). The bilateral femoral fractures developed in 23 (30.2 %) of 76 patients and showed a high incidence in the group medicated more than three years (two/23 vs 21/23, p = 0.039). CONCLUSIONS: The longer bisphosphonates are used, the more the cases of delayed union and the more frequent the development of bilateral fractures following unilateral fractures. With regard to the delayed union, the methods of the acceleration of fracture healing may be beneficial in atypical femoral fracture patients who had been receiving long-term bisphosphonates therapy. Careful observation is required for contra-lateral femurs due to a high incidence of bilateral atypical femoral fractures.
PURPOSE: Increasing numbers of atypical femoral fractures have been reported among long-term bisphosphonate users. We evaluated clinical characteristics of atypical femoral fractures throughout Korean multicenter studies. METHODS: We retrospectively analysed the bone mineral density, prodromal symptoms before femoral fracture, and medication history of osteoporosis in 76 cases of atypical femoral fracture. RESULTS: The mean age of cases was 71.4 ± 8.8 (range, 43-89) years old. The mean follow-up period after the fracture operation was 24.5 ± 12.9 (range, 12-79) months. BMI was 23.2 ± 3.0 on average. The mean BMD of femur was -1.9 ± 1.4 (range, -4.8 to 1.3). Prodromal symptoms including thigh pain before femoral fracture appeared in 22 (28.9 %) of 76 patients. All patients included in the study used bisphosphonate. The duration of taking bisphosphonate before fracture was 36.8 ± 50.8 (one-204 months) months. Fifty-seven (75 %) of 76 patients were taking the medication for more than three years. Delayed union occurred in 43 (56.5 %) of 76 patients. Delayed union was defined as a fractured bone that did not completely heal within six months of injury. The group of having taken anti-osteoporotic medication for more than three years showed relatively longer union period compared to that for a shorter period medication group (4.8 ± 2.5 months vs 9.3 ± 3.7 months, p = 0.017). The delayed union developed in 43 (56.5 %) of 76 patients and showed a significantly higher incidence in the group with long-term therapy (five/43 vs 38/43, p = 0.021). The bilateral femoral fractures developed in 23 (30.2 %) of 76 patients and showed a high incidence in the group medicated more than three years (two/23 vs 21/23, p = 0.039). CONCLUSIONS: The longer bisphosphonates are used, the more the cases of delayed union and the more frequent the development of bilateral fractures following unilateral fractures. With regard to the delayed union, the methods of the acceleration of fracture healing may be beneficial in atypical femoral fracturepatients who had been receiving long-term bisphosphonates therapy. Careful observation is required for contra-lateral femurs due to a high incidence of bilateral atypical femoral fractures.
Authors: Patrick Haentjens; Jay Magaziner; Cathleen S Colón-Emeric; Dirk Vanderschueren; Koen Milisen; Brigitte Velkeniers; Steven Boonen Journal: Ann Intern Med Date: 2010-03-16 Impact factor: 25.391
Authors: Elizabeth Shane; David Burr; Peter R Ebeling; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David Dempster; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Kenneth Koval; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Howe Tet Sen; Marjolein C H van der Meulen; Robert S Weinstein; Michael Whyte Journal: J Bone Miner Res Date: 2010-11 Impact factor: 6.741
Authors: Per Aspenberg; Harry K Genant; Torsten Johansson; Antonio J Nino; Kyoungah See; Kelly Krohn; Pedro A García-Hernández; Christopher P Recknor; Thomas A Einhorn; Gail P Dalsky; Bruce H Mitlak; Anke Fierlinger; Mark C Lakshmanan Journal: J Bone Miner Res Date: 2010-02 Impact factor: 6.741
Authors: George Ioannidis; Alexandra Papaioannou; Wilma M Hopman; Noori Akhtar-Danesh; Tassos Anastassiades; Laura Pickard; Courtney C Kennedy; Jerilynn C Prior; Wojciech P Olszynski; Kenneth S Davison; David Goltzman; Lehana Thabane; Amiran Gafni; Emmanuel A Papadimitropoulos; Jacques P Brown; Robert G Josse; David A Hanley; Jonathan D Adachi Journal: CMAJ Date: 2009-08-04 Impact factor: 8.262
Authors: A Papaioannou; C C Kennedy; G Ioannidis; A Sawka; W M Hopman; L Pickard; J P Brown; R G Josse; S Kaiser; T Anastassiades; D Goltzman; M Papadimitropoulos; A Tenenhouse; J C Prior; W P Olszynski; J D Adachi Journal: Osteoporos Int Date: 2008-09-19 Impact factor: 4.507
Authors: Joan C Lo; Rita L Hui; Christopher D Grimsrud; Malini Chandra; Romain S Neugebauer; Joel R Gonzalez; Amer Budayr; Gene Lau; Bruce Ettinger Journal: Bone Date: 2016-01-06 Impact factor: 4.398
Authors: George R Matcuk; Scott R Mahanty; Matthew R Skalski; Dakshesh B Patel; Eric A White; Christopher J Gottsegen Journal: Emerg Radiol Date: 2016-03-22